Drugs / VOTUCALIS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00247520 | May → Aug 2005 | seasonal allergic rhinitis | Evolutec Group | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00353964 | — | eye adnexa disorder | Evolutec Group | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VOTUCALIS | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108351 ↗ |
| Known as | rEV131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00247520 ↗ |
| Modality | Protein / enzyme biologic | “rEV131, a histamine binding protein (derived from tick saliva)” NCT00247520 ↗ |
| Route | Intranasal | “by nasal spray” NCT00247520 ↗ |